PMID- 36289731
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230308
IS  - 2227-9059 (Print)
IS  - 2227-9059 (Electronic)
IS  - 2227-9059 (Linking)
VI  - 10
IP  - 10
DP  - 2022 Oct 2
TI  - Sex Differences in Oxycodone/Naloxone vs. Tapentadol in Chronic Non-Cancer Pain: 
      An Observational Real-World Study.
LID - 10.3390/biomedicines10102468 [doi]
LID - 2468
AB  - Despite the large body of research on sex differences in pain, there is a lack of 
      translation to real-world pain management. Our aim was to analyse the sex 
      differences in the analgesic response to oxycodone/naloxone (OXN) and tapentadol 
      (TAP), in comparison with other opioids (OPO) commonly prescribed for chronic 
      non-cancer pain (CNCP). An observational and cross-sectional study was conducted 
      on ambulatory CNCP patients (n = 571). Sociodemographic, clinical (pain 
      intensity, relief, and quality of life), safety (adverse events (AEs), adverse 
      drug reactions), hospital frequentations and pharmacological (morphine equivalent 
      daily dose (MEDD)) variables were collected. Multiple linear regressions were 
      carried out to assess the association between sex and outcomes. Sex differences 
      were observed, with lower female tolerability and higher hospital frequentation, 
      especially in the OXN group (OR AEs report = 2.8 [1.8-4.4], p < 0.001). Here, 
      females showed higher hospital use (23% hospital admission, 30% prescription 
      change, p < 0.05), requiring a higher MEDD (127 +/- 103 mg/day, p < 0.05), compared 
      to OXN men. Regardless of the opioid group, CNCP women were significantly older 
      than men (three years), with significantly higher benzodiazepine use (OR = 1.6 
      [1.1-2.3]), more constipation (OR = 1.34 [0.93-1.90]) and headache (OR = 1.45 
      [0.99-2.13]) AEs, than men who were more likely to refer sexual dysfunction (OR = 
      2.77 [1.53-5.01]), and loss of libido (OR = 1.93 [1.22-3.04]). Sex-differences 
      were found related to poorer female drug tolerability and higher hospital 
      resources, even worst in OXN female users. Other differences related to older 
      female ages and benzodiazepine prescription, need to be further analysed from a 
      gender perspective.
FAU - Barrachina, Jordi
AU  - Barrachina J
AUID- ORCID: 0000-0002-4697-2783
AD  - Neuropharmacology on Pain (NED), Alicante Institute for Health and Biomedical 
      Research (ISABIAL-FISABIO Foundation), c/Pintor Baeza, 12, 03010 Alicante, Spain.
FAU - Margarit, Cesar
AU  - Margarit C
AD  - Neuropharmacology on Pain (NED), Alicante Institute for Health and Biomedical 
      Research (ISABIAL-FISABIO Foundation), c/Pintor Baeza, 12, 03010 Alicante, Spain.
AD  - Pain Unit, Department of Health of Alicante-General Hospital, c/Pintor Baeza, 12, 
      03010 Alicante, Spain.
FAU - Muriel, Javier
AU  - Muriel J
AUID- ORCID: 0000-0003-0048-9451
AD  - Neuropharmacology on Pain (NED), Alicante Institute for Health and Biomedical 
      Research (ISABIAL-FISABIO Foundation), c/Pintor Baeza, 12, 03010 Alicante, Spain.
AD  - Pain Unit, Department of Health of Alicante-General Hospital, c/Pintor Baeza, 12, 
      03010 Alicante, Spain.
FAU - Lopez-Gil, Vicente
AU  - Lopez-Gil V
AUID- ORCID: 0000-0003-1280-6418
AD  - Occupational Observatory, Miguel Hernandez University of Elche, Avda. de la 
      Universidad s/n, 03202 Elche, Spain.
FAU - Lopez-Gil, Santiago
AU  - Lopez-Gil S
AUID- ORCID: 0000-0002-1792-9129
AD  - Occupational Observatory, Miguel Hernandez University of Elche, Avda. de la 
      Universidad s/n, 03202 Elche, Spain.
FAU - Ballester, Pura
AU  - Ballester P
AUID- ORCID: 0000-0002-7345-448X
AD  - Neuropharmacology on Pain (NED), Alicante Institute for Health and Biomedical 
      Research (ISABIAL-FISABIO Foundation), c/Pintor Baeza, 12, 03010 Alicante, Spain.
FAU - Mira-Lorente, Laura
AU  - Mira-Lorente L
AD  - Occupational Observatory, Miguel Hernandez University of Elche, Avda. de la 
      Universidad s/n, 03202 Elche, Spain.
FAU - Agullo, Laura
AU  - Agullo L
AUID- ORCID: 0000-0002-8739-0456
AD  - Neuropharmacology on Pain (NED), Alicante Institute for Health and Biomedical 
      Research (ISABIAL-FISABIO Foundation), c/Pintor Baeza, 12, 03010 Alicante, Spain.
FAU - Peiro, Ana M
AU  - Peiro AM
AUID- ORCID: 0000-0002-2385-3749
AD  - Neuropharmacology on Pain (NED), Alicante Institute for Health and Biomedical 
      Research (ISABIAL-FISABIO Foundation), c/Pintor Baeza, 12, 03010 Alicante, Spain.
AD  - Department of Pharmacology, Paediatrics and Organic Chemistry, Miguel Hernandez 
      University of Elche, Crta. Nacional, N-332. s/n, 03505 Sant Joan, Spain.
AD  - Clinical Pharmacology Unit, Department of Health of Alicante-General Hospital, 
      c/Pintor Baeza, 12, 03010 Alicante, Spain.
LA  - eng
PT  - Journal Article
DEP - 20221002
PL  - Switzerland
TA  - Biomedicines
JT  - Biomedicines
JID - 101691304
PMC - PMC9598624
OTO - NOTNLM
OT  - bias
OT  - chronic pain
OT  - oxycodone
OT  - sex
OT  - tapentadol
COIS- The authors declare no conflict of interest.
EDAT- 2022/10/28 06:00
MHDA- 2022/10/28 06:01
PMCR- 2022/10/02
CRDT- 2022/10/27 01:02
PHST- 2022/07/28 00:00 [received]
PHST- 2022/09/16 00:00 [revised]
PHST- 2022/09/30 00:00 [accepted]
PHST- 2022/10/27 01:02 [entrez]
PHST- 2022/10/28 06:00 [pubmed]
PHST- 2022/10/28 06:01 [medline]
PHST- 2022/10/02 00:00 [pmc-release]
AID - biomedicines10102468 [pii]
AID - biomedicines-10-02468 [pii]
AID - 10.3390/biomedicines10102468 [doi]
PST - epublish
SO  - Biomedicines. 2022 Oct 2;10(10):2468. doi: 10.3390/biomedicines10102468.